Oncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy
|
|
- Angelica McDonald
- 8 years ago
- Views:
Transcription
1 Oncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy Michael A. Postow, M.D. Memorial Sloan Kettering Cancer Center Wednesday, June 10, :00 a.m. EDT Brought to you by the Cancer Research Institute
2 Tweet your comments and questions to using #CRIwebinar
3 Today s Host Brian M. Brewer Director of Marketing and Communications Cancer Research Institute
4 Today s Presenter Michael A. Postow, M.D. Medical Oncologist, Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
5 Putting Cancer in Check with Immunotherapy: Melanoma and Beyond Michael Postow, M.D. Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
6 Bristol-Myers Squibb: Research support Participated in an advisory council (non-paid) Amgen: Participated in an advisory council (non-paid)
7 2013 Breakthrough of the Year
8 What happened in 1891?
9 What happened in 1891?
10 What happened in 1891?
11 Main Questions 1. How can the immune system treat cancer? 2. What have we learned from clinical experience in melanoma? 3. How can we improve?
12 Immunotherapy = T cell kills a cancer cell
13 Immunity in tumor control Mellman et al. Nature 2011
14
15 Immunity in tumor control Vaccines Cytokines Adoptive cell transfer Immunomodulatory antibodies Mellman et al. Nature 2011
16 Sipuleucel-T vaccine improves survival in metastatic prostate cancer Kantoff PW et al. NEJM 2010
17 HD IL-2 Therapy: Durable Responses HD IL-2 produces durable responses in 6% to 10% of patients with advanced melanoma or RCC Few relapses in patients responding for over 2.5 years (likely cured) FDA approval in 1992 (RCC) and 1997 (melanoma) Metastatic Melanoma (N = 270) Metastatic RCC (N = 255) Probability of Continuing Response CR (n = 17) PR (n = 26) CR + PR (n = 43) Duration of Response (Mos) Probability of Continuing Response CR PR All Duration of Response (Mos) Atkins MB et al. J Clin Oncol 1999
18 Immunity in tumor control Vaccines Cytokines Adoptive cell transfer Immunomodulatory antibodies Mellman et al. Nature 2011
19 Ways to keeping the T cells active Turning up the Activating Blocking the Inhibiting Mellman et al. Nature 2011
20 Ways to keeping the T cells active Turning up the Activating Blocking the Inhibiting Mellman et al. Nature 2011
21 Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) Postow et al. JCO 2015
22 PD-1 Immune Checkpoints Postow et al. JCO 2015
23 Blocking immunologic checkpoints Kyi and Postow FEBS Letters 2014
24 Adverse Events CTLA-4: Rash, diarrhea, hepatitis, endocrine 24% grade 3/4 (1) PD-1/PD-L1: Rash, fatigue, arthralgias 6-12% grade 3/4 (2-4) Chemotherapy: Alopecia, nausea, myelosuppression ~50% grade 3/4 (5) (1) Hodi et al. NEJM 2010 (2) Hamid et al. NEJM 2013 (3) Topalian et al. NEJM 2012 (4) Weber et al. Lancet Oncol 2015 (5) Kelly et al. JCO 2001
25 Ipilimumab rashes Can be treated with topical corticosteroids
26 Diarrhea and Colitis Slangen et al. World J Gastrointest Pharmacol Ther 2013
27 Diarrhea and Colitis Focal Active Colitis Alterations in Crypt Epithelium Maker AV Ann Surg Oncol 2005
28 Enlarged pituitary due to hypophysitis Weber et al. JCO 2012, reprinted from Blansfield J Immunother 2005
29 Pneumonitis 2/21/2011 3/30/2011 Two doses of ipilimumab and four of nivolumab
30 Kinetics of iraes with ipilimumab Weber JS J Clin Oncol 2012
31
32 Diarrhea/Colitis Management
33 Blocking immunologic checkpoints
34 Antibodies that block CTLA-4 Ipilimumab Tremelimumab
35 Ipilimumab confers OS benefit to gp100 vaccine in phase III study Median OS 10.1 mos 24% alive at 2 years Response rate of 10.9% Hodi et al. NEJM 2010
36 Long-term results of 2 nd phase III study Median OS 11.2 vs. 9.1 mos At 5 years, 18.2 vs. 8.8% alive, p=0.002 Maio et al. J Clin Oncol 2010
37 Ipilimumab responses can be delayed Pre-treatment Week 12: Progression 10 mg/kg ipilimumab Q3W X 4 July 2006 New lesions Week 20: Regression Week 36: Still Regressing Wolchok ASCO 2008
38 Immune-related response criteria New lesions are not counted automatically as progressive disease. Increase in tumor burden must be confirmed on subsequent scan. Wolchok et al. Clin Cancer Res 2009
39 Blocking immunologic checkpoints Kyi and Postow FEBS Letters 2014
40 PD-1 Immune Checkpoints MHC and Antigen T-Cell Receptor PD-1 PD-L1 Dendritic Cell B7 PD-L1/PD-L2 CD28 PD-L1 T Cell Tumor PD-1 PD-1 PD-L1 Lymph Node Tumor Microenvironment Postow et al. JCO 2015
41 PD-1/PD-L1 agents in development Target Agent Class PD-1 PD-L1 Nivolumab (MDX-1106, BMS ) Pembrolizumab (MK-3475) Pidilizumab (CT-011) AMP-224 BMS (MDX-1105) Atezolizumab (MPDL3280A) MEDI4736 IgG4 fully human Ab IgG4 engineered humanized Ab IgG1 humanized Ab Fc of human IgG-PD-L2 fusion IgG4 fully human Ab IgG1 engineered fully human Ab IgG1 engineered fully human Ab Avelumab (MSB C) IgG1 fully human Ab
42 Responses with Nivolumab Response rate: ~30% Nivolumab: 1mg/kg every 2 weeks in melanoma patients Topalian et al. NEJM 2012
43 Nivolumab improves OS Nivolumab vs. DTIC - HR: 0.42 Robert et al. NEJM 2015
44 Pembrolizumab: Clinical Activity Baseline: April 13, 2012 April 9, year-old male with symptomatic progression after bio-chemotherapy, HD IL-2, and ipilimumab Images courtesy of A. Ribas, UCLA
45 Pembrolizumab improves OS compared to ipilimumab Robert et al. NEJM 2015
46 Efficacy of PD-1 Agents
47 Efficacy of PD-1 Agents Drug Sponsor Target Disease Type Response (n) Reference Solid Tumors 21% (42) Topalian et al. NEJM 2012 Melanoma 32% (44) Weber et al. JCO 2013 Nivolumab BMS PD-1 NSCLC 14% (63) Antonia et al. WCLC 2013 RCC 21% (168) Motzer et al. ASCO 2014 Ovarian 17% (18) Hamanishi et al. ASCO 2014 Melanoma 40% (113) Daud et al. AACR 2014 NSCLC 19% (146) Gandhi et al. AACR 2014 Pembrolizumab Merck PD-1 Melanoma 34% (411) Ribas ASCO 2014 NSCLC 26% (45) Rizvi et al. ASCO 2014 Head and Neck 18% (55) Selwert et al. ASCO 2014 CT-011 Curetech PD-1 Hematologic Cancers 33% (17) Berger et al. Clin Cancer Res 2008 Melanoma 6% (101) Atkins ASCO 2014 AMP-224 Amplimmune/ GSK PD-1 Solid tumors Response, SD (42) Infante et al. ASCO 2013
48 Efficacy of PD-L1 Agents Drug Sponsor Target Disease Type Response (n) Reference Atezolizumab (MPDL3280A) Genentech PD-L1 MEDI4736 MedImmune PD-L1 Avelumab (MSB C) EMD Serono / Pfizer PD-L1 Solid Tumors 21% (103) Herbst et al. ASCO 2013 Melanoma 23% (30) Hamid et al. ASCO 2013 NSCLC 23% (53) Sorial et al. ECC 2013 Bladder 26% (65) Powels et al. ASCO 2014 Solid Tumors 11% (179) Segal et al. ASCO 2014 NSCLC 16% (58) Brahmer et al. ASCO 2014 Head & Neck 14% (22) Segal et al. ASCO 2014 Gastric 19% (16) Segal et al. ASCO 2014 Solid tumors Response (27) Heery et al. ASCO 2014 MDX-1105 BMS PD-L1 Solid Tumors 17% (135) Brahmer et al. NEJM 2012
49 Efficacy of PD-L1 Agents Drug Sponsor Target Disease Type Response (n) Reference Atezolizumab (MPDL3280A) Genentech PD-L1 MEDI4736 MedImmune PD-L1 Avelumab (MSB C) EMD Serono / Pfizer PD-L1 Solid Tumors 21% (103) Herbst et al. ASCO 2013 Melanoma 23% (30) Hamid et al. ASCO 2013 NSCLC 23% (53) Sorial et al. ECC 2013 Bladder 26% (65) Powels et al. ASCO 2014 Solid Tumors 11% (179) Segal et al. ASCO 2014 NSCLC 16% (58) Brahmer et al. ASCO 2014 Head & Neck 14% (22) Segal et al. ASCO 2014 Gastric 19% (16) Segal et al. ASCO 2014 Solid tumors Response (27) Heery et al. ASCO 2014 MDX-1105 BMS PD-L1 Solid Tumors 17% (135) Brahmer et al. NEJM 2012
50 Response in Patient with Head and Neck Cancer Baseline Day y.o. female Progressed on previous cetuximab HPV negative, PD-L1 positive Treatment ongoing at 8 weeks Segal et al. ASCO 2014
51 MPDL3280A: Urothelial Bladder Cancer Median time to first response was 42 days (range, 38 to 85 days) Median duration of response has not been reached T Powles et al. ASCO 2014
52 Pembrolizumab: AEs in > 5% of Patients Adverse Event (N = 135) All Grades, n (%) Grades 3/4, n (%) Any 107 (79.3) 17 (12.6) Fatigue 41 (30.4) 2 (1.5) Rash 28 (20.7) 3 (2.2) Pruritus 28 (20.7) 1 (0.7) Diarrhea 27 (20.0) 1 (0.7) Myalgia 16 (11.9) 0 Headache 14 (10.4) 0 Increased AST 13 (9.6) 2 (1.5) Asthenia 13 (9.6) 0 Nausea 13 (9.6) 0 Vitiligo 12 (8.9) 0 Hypothyroidism 11 (8.1) 1 (0.7) Increased ALT 11 (8.1) 0 Cough 11 (8.1) 0 Pyrexia 10 (7.4) 0 Chills 9 (6.7) 0 Abdominal pain 7 (5.2) 1 (0.7) A Ribas et al. ASCO 2013
53 Immunohistochemistry for PD-L1 expression PD-L1 Negative PD-L1 Positive PD-L1 tumor cell membrane staining: 0 3%, focal 5%, heterogeneous 80%, homogeneous Slide courtesy of Margaret Callahan
54 Nivolumab in NSCLC: PD-L1 is not associated with overall survival PD-L1 + PD-L1 - Julie Brahmer ASCO 2014
55 PD-L1 EGFR, BRAF, HER2, ER, KRAS Many different assays measure PD-L1 differently PD-L1 negative tumors can still respond PD-L1 is a dynamic immunologic marker Heterogeneity exists within individual patients [1] [1] Madore et al. Pigment Cell Melanoma Res 2014
56 Pre-treatment immunologic biomarkers Square peg into a round hole?
57 Immune Checkpoint Combinations Chemotherapy Carboplatin/Paclitaxel (Lynch et al. J Clin Oncol 2012) Anti-angiogenic agents Bevacizumab (Hodi et al. Cancer Immunol Res 2014) Hormonal Therapy Exemestane (Vonderheide et al. Clin Cancer Res 2010) Androgen deprivation (MDACC) Targeted therapy Vemurafenib (Ribas et al. NEJM 2013) Other immunotherapy GM-CSF (Hodi et al. JAMA 2014) Nivolumab (Wolchok et al. NEJM 2013 and Postow et al. NEJM 2015) Radiotherapy Postow et al. NEJM 2013
58 Ipilimumab + Nivolumab vs. Ipilimumab Response rate: 61% vs. 11% Postow et al. NEJM 2015
59 Summary Durable responses in melanoma and other cancers Biomarkers inform biology but not yet treatment selection Combinations have promise but are they better than single agents?
60 1891 to 2015
61 1891 to 2015
62 Q&A: Ask an Expert Michael A. Postow, M.D. Medical Oncologist, Melanoma-Sarcoma Oncology Service Memorial Sloan Kettering Cancer Center Follow along using #CRIwebinar
63 Upcoming Webinars Jeffrey S. Weber, M.D., Ph.D. Cancer Revealed: How Our Immune System Sees and Destroys Tumors June 16, 2015, at 2:00 p.m. EDT David A. Reardon, M.D. Aiming the Immune System at Brain Cancer June 23, 2015, at 12:00 p.m. EDT Jedd D. Wolchok, M.D., Ph.D. Getting to Cures: The Next Five Years in Immunotherapy June 25, 2015, at 2:00 p.m. EDT Register today at
64
65
66
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationBADO meeting. Immunotherapy. in Metastatic Melanoma
BADO meeting Immunotherapy in Metastatic Melanoma UCL Université catholique de Louvain Prof J-Fr. BAURAIN Medical Oncology Department BADO Meeting Inaugural Lecture 07 december 2013 Melanoma Treatment
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationMelanoma and Immunotherapy
Melanoma and Immunotherapy Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA The Transformed Landscape
More informationFoundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationImmunotherapy for High-Risk and Metastatic Melanoma
Immunotherapy for High-Risk and Metastatic Melanoma Timothy M. Kuzel, MD Professor of Medicine and Dermatology Feinberg School of Medicine Northwestern University Chicago ICLIO 1 st Annual National Conference
More information10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
More informationASCO 12. PD-1 Immunotherapy Makes a Splash at ASCO
PD-1 Immunotherapy Makes a Splash at ASCO By Gregory R. Wolfe, PhD Epigenetic variation and genetic instability in tumor cells yield a variety of tumor antigens that the immune system can recognize to
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationTargeted immunotherapy: unleashing the immune system against cancer
Targeted immunotherapy: unleashing the immune system against cancer Suzanne L. Topalian, MD Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center 2013 MMS Annual Education
More informationPredictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy
Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center Michael Atkins, MD Consulting Fees (e.g., advisory
More informationImmuno-Oncology, The New Era of Cancer Treatment. Ted Lee, MD, MPH Disease Area Head, IO, Pac Rim, Bristol Myers Squibb
Immuno-Oncology, The New Era of Cancer Treatment Ted Lee, MD, MPH Disease Area Head, IO, Pac Rim, Bristol Myers Squibb 1 Disclosures Dr. Ted Lee is an employee of Bristol-Myers Squibb Co. New Therapies
More informationCombination Immunotherapies: Melanoma
Combination Immunotherapies: Melanoma Igor Puzanov, MD, MSCI, FACP Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Research, Clinical Director, Renal
More informationComparing Immunotherapy with High Dose IL-2 and Ipilimumab
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC mike.wong@med.usc.edu Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
More informationCurrent Status of Immunotherapy For the Treatment of Metastatic Melanoma
Current Status of Immunotherapy For the Treatment of Metastatic Melanoma The 2016 Arizona Clinical Oncology Society Meeting Richard W. Joseph, MD Assistant Professor Mayo Clinic Florida joseph.richard@mayo.edu
More informationImmunotherapy for Metastatic Renal Cell Carcinoma
Immunotherapy for Metastatic Renal Cell Carcinoma Timothy M. Kuzel, MD Professor of Medicine and Dermatology Feinberg School of Medicine Northwestern University Chicago, Ilinois ICLIO 1 st Annual National
More informationTKCC/Garvan Cancer Biology Seminars Melanoma & Cancer Immunotherapy
TKCC/Garvan Cancer Biology Seminars Melanoma & Cancer Immunotherapy 19/02/2016 A/Prof Anthony Joshua Head, Dept of Medical Oncology St Vincent s Hospital, Sydney Immunotherapy Progress: A Long Time Coming
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationBOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05
Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:
More informationCancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview
Brochure More information from http://www.researchandmarkets.com/reports/3066973/ Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Description:
More informationAttached from the following page is the press release made by BMS for your information.
July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationAnticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY
Anticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY A robust new approach Since its inception in the mid-0th century, chemotherapy has been the mainstay of
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationImmuno-Oncology 2015: A New Landscape in Lung Cancer
Immuno-Oncology 2015: A New Landscape in Lung Cancer David R. Spigel, M.D. Lung Cancer Program Director Sarah Cannon Research Institute/Tennessee Oncology, PLLC Nashville, TN Off-Label Use Disclosure(s)
More informationImmune Therapy for Pancreatic Cancer
Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:
More informationPROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
More informationThe Past, Present & Future of Cancer Immunotherapy:
Article The Past, Present & Future of Cancer Immunotherapy: An Overview Recently BioWorld called cancer immunotherapy white hot based on unprecedented investments in private companies, partnerships between
More informationDisclosures. Disclosures. Grand Unification: The rationale for combining immunotherapy and molecular targeted therapy 25/02/2014
Grand Unification: The rationale for combining immunotherapy and molecular targeted therapy Ryan J. Sullivan, M.D. Massachusetts General Hospital / Harvard University Canadian Melanoma Conference February
More informationEnhancing Anti-Tumor Activity of Checkpoint Inhibition
Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor
More informationCoordinating Immune Checkpoint Blockade For Cancer Immunotherapy In Combination
Coordinating Immune Checkpoint Blockade For Cancer Immunotherapy In Combination Jennifer Mataraza, Ph.D. Senior Investigator Immune Oncology, NIBR March 25, 2015 (Image: Steve Gshmeisserner/Science Photo
More informationAdditional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points
News Release Media Contacts: Annick Robinson Dominique Quirion Merck NATIONAL Annick.robinson@merck.com dquirion@national.ca 514 428-2890 514 843-2302 Investor Contacts: Justin Holko: (+1 908-423-5088
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationImmunotherapy for Melanoma: The End of The Beginning. Jedd D. Wolchok, MD, PhD
Immunotherapy for Melanoma: The End of The Beginning Jedd D. Wolchok, MD, PhD ME SL K RI M A - O ER NG E High-Dose IL-2 Therapy* Probability of continuing response 1.0 0.8 0.6 0.4 0.2 0.0 CR (n = 17)
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationNews Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor
More informationLatest advances in the treatment of mesothelioma
Latest advances in the treatment of mesothelioma Assoc Prof Thomas John Medical Oncologist, NHMRC Fellow Olivia Newton-John Cancer Research Institute 28 th March 2015 Disclosures Nil relevant Honoraria:
More informationYour Immune System & Lung Cancer Treatment
Your Immune System & Lung Cancer Treatment Immunotherapy and Lung Cancer Immunotherapy is quickly developing as an important approach to treating many forms of cancer, including lung cancer. Immunotherapy
More informationGrade 4 Thrombocytopenia During. Predictor of Response in Melanoma but Not in Renal Cell Cancer.
Grade 4 Thrombocytopenia During Treatment with High-Dose IL-2 2 (HD IL-2) is a Predictor of Response in Melanoma but Not in Renal Cell Cancer. Timothy E. Bael, M.D. Bercedis L. Peterson, Ph.D. Karima Rasheed,
More informationBiomarkers and Associations With the Clinical Activity of PD-L1 Blockade in a MPDL3280A Study
Biomarkers and Associations With the Clinical Activity of PD-L1 Blockade in a MPDL3280A Study Powderly J 1, Koeppen H 2, Hodi FS 3, Sosman J 4, Gettinger S 5, Desai R 2, Tabernero J 6, Soria JC 7, Hamid
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER BOOKLET SUPPLEMENT Immunotherapy Immunotherapy is one of the most exciting new approaches for treating several types of cancer, including lung cancer. Immunotherapies
More informationImmunoteràpia en el Limfoma de Hodgkin
Immunoteràpia en el Limfoma de Hodgkin A. Sureda Servei d Hematologia Institut Català d Oncologia - Hospitalet SCHH. Barcelona, 22 de juny de 2016 OS from relapse after an ASCT. The experience of the LWP
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationMedia Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986
News Release Media Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986 Merck Announces Initial Results for Pembrolizumab with Novel Immunotherapy Combinations from Three
More informationPfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will
More informationImmunotherapy or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma?
Immunotherapy or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma? Geoffrey T. Gibney, MD, and Michael B. Atkins, MD Geoffrey T. Gibney, MD, is an attending
More informationCONTINUING EDUCATION FACULTY. Kathy Boltz, PhD. Phoenix, Arizona
CONTINUING EDUCATION EDUCATIONAL OBJECTIVES After participating in this activity, clinicians should be better able to Identify the components of the immune system Describe the mechanism of action of various
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationMetastatic Melanoma What You Need to Know
ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients
More informationYour Immune System & Melanoma Treatment
Your Immune System & Melanoma Treatment Immunotherapy and Melanoma Immunotherapy is rapidly emerging as an important approach to treating many forms of cancer. For people with melanoma, the news is particularly
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationImmune checkpoint inhibitors in clinical trials
Chinese Journal of Cancer Review Immune checkpoint inhibitors in clinical trials Elad Sharon 1, Howard Streicher 1, Priscila Goncalves 2 and Helen X. Chen 1 Abstract Immunology-based therapy is rapidly
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationAdvances in immunotherapy for melanoma
Redman et al. BMC Medicine (2016) 14:20 DOI 10.1186/s12916-016-0571-0 MINIREVIEW Open Access Advances in immunotherapy for melanoma Jason M. Redman 1,2, Geoffrey T. Gibney 1,2 and Michael B. Atkins 1,2*
More informationIMMUNOTHERAPY OF MELANOMA Anti PD1 Takes Center Stage. Dr Peter Hersey Professor of Melanoma Biology University of Sydney
IMMUNOTHERAPY OF MELANOMA Anti PD1 Takes Center Stage Dr Peter Hersey Professor of Melanoma Biology University of Sydney What we have learnt about immunotherapy over the past 3 years Inhibition of Physiologic
More informationThe renaissance of immunotherapy is a revolution for cancer patients. Ira Mellman, Ph.D. Vice President, Cancer Immunology, Genentech
The renaissance of immunotherapy is a revolution for cancer patients Ira Mellman, Ph.D. Vice President, Cancer Immunology, Genentech 1 This presentation contains certain forward-looking statements. These
More informationThis report focuses on the rising potential for the newest and most promising of cancer treatments:
1 Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies Allan B. Haberman. Ph.D. This report focuses on the rising potential for the newest and most promising
More informationCorporate Presentation June 2, 2015
Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these
More informationOpdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer
June 28, 2016 Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer (PRINCETON, NJ, June 27, 2016) - Bristol-Myers Squibb
More informationImmunotherapy in Oncology The New Era of Cancer Treatment
Immunotherapy in Oncology The New Era of Cancer Treatment Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Statement of Disclosure I have no relevant financial
More informationISSUE BRIEF Conference on Clinical Cancer Research November 2013
ISSUE BRIEF Conference on Clinical Cancer Research November 2013 No Facilitating the Development of Immunotherapies: Cancer Research Intermediate Endpoints for Immune Checkpoint Modulators Axel Hoos, Vice
More informationRapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
Bostwick et al. Journal for ImmunoTherapy of Cancer (2015) 3:19 DOI 10.1186/s40425-015-0064-2 CASE REPORT Open Access Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy
More informationOutline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice
Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER
AFA 08958 From Bench to Bedside From KK DT1 10/27/2015 12:04 PM 01 ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER Hak Choy, MD University of Texas Southwestern Medical Center Dallas, Texas, USA Orchestrating
More informationImmune Checkpoint Blockade in Acute Myeloid Leukemia. Kinsey McCormick Hematology Fellow s Conference January 10, 2014
Immune Checkpoint Blockade in Acute Myeloid Leukemia Kinsey McCormick Hematology Fellow s Conference January 10, 2014 Overview Overview of immune checkpoints Immune checkpoints as mechanism of immune evasion
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation May 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation May 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationBioinformatics for cancer immunology and immunotherapy
Bioinformatics for cancer immunology and immunotherapy Zlatko Trajanoski Biocenter, Division for Bioinformatics Innsbruck Medical University Innrain 80, 6020 Innsbruck, Austria Email: zlatko.trajanoski@i-med.ac.at
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationPD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationEmerging Therapies for the Treatment of Advanced Melanoma: Focus on Immunotherapy
Emerging Therapies for the Treatment of Advanced Melanoma: Focus on Immunotherapy Presented as a Midday Symposium and Live Webinar at the 50 th ASHP Midyear Clinical Meeting and Exhibition Monday, December
More informationMesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam
Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationCancer Immunotherapy
Cancer Immunotherapy What is cancer immunotherapy? Immunotherapy is treatment that uses certain parts of a person s immune system to fight diseases such as cancer. This can be done in a couple of ways.
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationCancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
More informationImmune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an Innocent Bystander
Toxins 2014, 6, 914-933; doi:10.3390/toxins6030914 Article OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationGUSTAVE ROUSSY AT ASCO
GUSTAVE ROUSSY AT ASCO PRESS RELEASE 30 MAY 03 JUNE MELANOMA www.gustaveroussy.fr/asco 30 MAY 03 JUNE 14 GUSTAVE ROUSSY AT ASCO PRESS RELEASE ASCO MAY 30 th - JUNE 3 rd 50 th congress American Society
More informationEquity markets Major advances in cancer therapeutics 18 August 2015
Major advances in cancer therapeutics 18 August 2015 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com Our cancer therapeutics investment theme recommends companies that
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationLUNG CANCER TREATMENTS. What you need to know about... immunotherapy
LUNG CANCER TREATMENTS What you need to know about... immunotherapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people with lung cancer
More informationPredictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University
Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Changing Paradigms in Cancer Treatment Potential Uses of Biomarkers Adverse event
More informationTargeted Therapy for Lung Cancer: The Greater Impact in the New Era
Targeted Therapy for Lung Cancer: The Greater Impact in the New Era Fadlo Raja Khuri, MD Professor and Roberto C. Goizueta Chair Department of Hematology & Medical Oncology Deputy Director Winship Cancer
More informationImmuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
More informationEnding cancer. Together.
Ending cancer. Together. Making History by Being First To achieve something as big and bold as ending cancer requires the courage to be first and a willingness to partner with others. At the Robert W.
More informationThis regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs
Regimen : Ipilimumab for Advanced Melanoma ICD10 code Codes pre-fixed with C43. Indication Regimen detail Ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma
More informationCancer Immunotherapy
Cancer Immunotherapy What is cancer immunotherapy? Immunotherapy is treatment that uses certain parts of a person s immune system to fight diseases such as cancer. This can be done in a couple of ways:
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More information